Barinthus Biotherapeutics (BRNS) Gains from Sales and Divestitures (2021)

Barinthus Biotherapeutics (BRNS) reported Gains from Sales and Divestitures of $514923.0 for Q4 2021, little changed quarter-over-quarter from $514923.0 in Q3 2021.

Barinthus Biotherapeutics (BRNS) Gains from Sales and Divestitures (2021) Analysis & Trends

Barinthus Biotherapeutics has reported Gains from Sales and Divestitures for 1 years, with the latest figure at $514923.0 in Q4 2021.

  • For the quarter ending Q4 2021, Gains from Sales and Divestitures changed N/A year-over-year to $514923.0; the trailing twelve-month figure through Dec 2021 stood at $514923.0 (changed N/A YoY), and the FY2021 full-year result was $514923.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures for Q4 2021 stood at $514923.0, roughly flat from $514923.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $514923.0 in Q2 2021, with the low at $514923.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn -
7 Psyence Biomedical 238.34 Bn 238.33 Bn -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn
9 Abivax 95.45 Bn 95.45 Bn -
10 Barinthus Biotherapeutics 27.57 Mn -39.54 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 514,923.00
Dec 31, 2021 514,923.00
Sep 30, 2021 514,923.00
Sep 30, 2021 514,923.00
Jun 30, 2021 514,923.00
Jun 30, 2021 514,923.00